By Elaine Chen, Allison DeAngelis, and Adam Feuerstein

Sept. 26, 2024

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle cell drug off global markets? And what cake did Adam make for all his podcast colleagues except Elaine?

We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech’s decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results.

advertisement

We also chat about the latest news in the life sciences, including Pfizer’s sudden announcement to pull its sickle cell drug and the imminent approval of Bristol Myers Squibb’s schizophrenia treatment.

For more on Genentech’s cancer pivot, go here; for more on Akeso’s ambitions, go here; and for more on Pfizer’s withdrawal of its sickle cell drug, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

advertisement

, ,
Submit a correction requestReprints

  1. Elaine Chen

    National Biotech Reporter

    Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

  2. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

  3. Adam Feuerstein

    Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.